205 related articles for article (PubMed ID: 35979992)
1. Preoperative PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers.
Wang J; Liu L; Pang H; Liu L; Jing X; Li Y
Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1315-1327. PubMed ID: 35979992
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [
Glickman A; Paredes P; Carreras-Diéguez N; Niñerola-Baizán A; Gaba L; Pahisa J; Fusté P; Del Pino M; Díaz-Feijóo B; González-Bosquet E; Agustí N; Sánchez-Izquierdo N; Fuster D; Perissinotti A; Romero I; Fernández-Galán E; Carrasco JL; Gil-Ibáñez B; Torné A
Eur Radiol; 2022 Apr; 32(4):2200-2208. PubMed ID: 34586465
[TBL] [Abstract][Full Text] [Related]
3.
Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
[TBL] [Abstract][Full Text] [Related]
4. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
[TBL] [Abstract][Full Text] [Related]
5. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
6. Preoperative serum level of CA153 and a new model to predict the sub-optimal primary debulking surgery in patients with advanced epithelial ovarian cancer.
Jia Y; Jiang Y; Fan X; Zhang Y; Li K; Wang H; Ning X; Yang X
World J Surg Oncol; 2024 Feb; 22(1):64. PubMed ID: 38395933
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of metabolic 18F-FDG PET/CT parameters and hematological prognostic indicators in patients with colorectal cancer.
Cengiz A; Yersal Ö; Ömürlü İK; Yürekli Y
Indian J Cancer; 2023; 60(2):224-229. PubMed ID: 37530245
[TBL] [Abstract][Full Text] [Related]
8. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of the
Goksel S; Cengiz A; Ozturk H; Yurekli Y
J Cancer Res Ther; 2021; 17(4):925-930. PubMed ID: 34528543
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Performance of F-18 FDG PET/CT Compared with CA125, HE4, and ROMA for Epithelial Ovarian Cancer.
Lee SS; Park JS; Lee KB; Jeong DH; Byun JM; Lee SM
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1123-1127. PubMed ID: 33906304
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
13. The value of
Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
[TBL] [Abstract][Full Text] [Related]
14. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
15. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
Fasmer KE; Gulati A; Dybvik JA; Ytre-Hauge S; Salvesen Ø; Trovik J; Krakstad C; Haldorsen IS
Eur Radiol; 2020 May; 30(5):2443-2453. PubMed ID: 32034487
[TBL] [Abstract][Full Text] [Related]
16. The ability of whole-body SUVmax in F-18 FDG PET/CT to predict suboptimal cytoreduction during primary debulking surgery for advanced ovarian cancer.
Chong GO; Jeong SY; Lee YH; Lee HJ; Lee SW; Han HS; Hong DG; Lee YS
J Ovarian Res; 2019 Feb; 12(1):12. PubMed ID: 30717813
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
[TBL] [Abstract][Full Text] [Related]
19. The significant value of predicting prognosis in patients with colorectal cancer using
Xu J; Li Y; Hu S; Lu L; Gao Z; Yuan H
Ann Nucl Med; 2019 Jan; 33(1):32-38. PubMed ID: 30218280
[TBL] [Abstract][Full Text] [Related]
20. Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.
Palomar Muñoz A; Cordero García JM; Talavera Rubio MDP; García Vicente AM; Pena Pardo FJ; Jiménez Londoño GA; Soriano Castrejón Á; Aranda Aguilar E
Medicine (Baltimore); 2018 Apr; 97(17):e0098. PubMed ID: 29702969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]